DGAP-News

Achievement of multiple milestones in Evotec's drug discovery alliances

DGAP-News: Evotec AG / Key word(s): Miscellaneous
Achievement of multiple milestones in Evotec's drug discovery
alliances

18.12.2014 / 17:30

---------------------------------------------------------------------

Hamburg, Germany - 18 December 2014: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) disclosed today that it achieved multiple
milestones in ongoing alliances with its strategic research partners. The
milestones were reached in its multi-target collaboration with Bayer
HealthCare ("Bayer") in endometriosis and within its partnership with
Janssen Pharmaceuticals, Inc. ("Janssen") for the EVT100 series for the
treatment of CNS diseases. These milestones trigger revenues of approx. EUR
8 m in total which will be recognised in the financial year 2014.

Multi-target collaboration with Bayer
In its multi-target collaboration with Bayer, Evotec has reached important
milestones for the transition of certain molecules into pre-clinical
development for the treatment of endometriosis. These milestones were
achieved under the agreement between Evotec and Bayer signed in October
2012. The goal of this collaboration is to identify three clinical
candidates within the five-year alliance. Both parties contribute
innovative drug targets and high-quality technology infrastructures and
share the responsibility for early research and pre-clinical
characterisation of potential clinical candidates in the disease area of
endometriosis.

Cooperation with Janssen
In its collaboration with Janssen on a NR2B subtype selective
NMDA-antagonist portfolio for development against CNS diseases, Evotec has
reached an important validation milestone for a new compound.


ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology, inflammation and infectious
diseases. Evotec has long-term discovery alliances with strategic partners
including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen
Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the
Company has existing development partnerships and product candidates both
in clinical and pre-clinical development. These include partnerships with